Julie Khlevner, MD, AGAFAssociate Professor of Pediatrics at Columbia University Medical CenterChair, NASPGHAN Neurogastroenterology and Motility Committee. 

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation

On May 27, 2026, Ironwood Pharmaceuticals' linaclotide (Linzess)

 for pediatric patients aged ≥2 years with functional constipation (FC).

Previously approved for FC in children aged ≥6 years, the expanded indication extends access to linaclotide for children aged 2–5 years with FC. Linaclotide remains the only FDA-approved prescription therapy for pediatric FC.

“Functional constipation is one of the most common conditions we treat, and younger children unfortunately have very limited evidence-based treatment options across multiple disorders and diseases,” Julie Khlevner, MD, a pediatric gastroenterologist at Columbia University Vagelos College of Physicians and Surgeons and an associate professor at Columbia University Medical Center, said in an interview with 

. “This is especially important for functional constipation when dietary changes, behavioral interventions, and over-the-counter laxatives are just not enough.”

FC in pediatric patients accounts for roughly 3% of general pediatric visits and up to 25% of pediatric gastroenterology referrals. Peak incidence occurs between ages 2 and 4 years and affects up to 35% of children aged <6 years.

Linaclotide is a guanylate cyclase-C agonist designed to increase intestinal fluid secretion, accelerate intestinal transit, and decrease the activity of pain-sensing nerves in the intestine.

The FDA approval for children aged 2–5 years was supported by data from a 12-week phase 3 randomized, placebo-controlled clinical trial evaluating linaclotide in pediatric patients with FC. In the study, linaclotide 72 mcg demonstrated improvement in spontaneous bowel movement frequency compared with placebo.

The safety profile of linaclotide observed in the trial was generally consistent with the established safety profile seen in adults with chronic idiopathic constipation and older pediatric patients with FC. Khlevner emphasized the importance of clinicians discussing potential adverse events with patients and caregivers.

“Counseling families on the possible side effects is always important. Caregivers should understand both the expected therapeutic effects and the signs that warrant medical attention. Providing clear guidance on when to contact the healthcare team can help ensure prompt management of any adverse event.”

Editor’s Note: Khlevner reports relevant disclosures with AbbVie and Ironwood.

Brooks A. FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years And Older. HCPLive. Published May 27, 2026. Accessed June 3, 2026. 

https://www.hcplive.com/view/fda-approves-linaclotide-linzess-for-functional-constipation-in-patients-2-years-and-older

Levy EI, Lemmens R, Vandenplas Y, Devreker T. Functional constipation in children: challenges and solutions. 

Pediatric Health, Medicine and Therapeutics

Videos

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

FDA News

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

May was a busy month in gastroenterology, marked by regulatory approvals, practice-changing data presentations at Digestive Disease Week (DDW) 2026, and continued advances in the management of 

 and eosinophilic esophagitis (EoE). From expanded treatment options for pediatric patients to promising new therapies for difficult-to-treat manifestations of Crohn’s disease (CD) and 

, the month highlighted the rapid pace of innovation across the specialty.

Among the notable regulatory developments were approvals from the US Food and Drug Administration (FDA) for single-dose vials of famotidine injection and an expanded pediatric indication for linaclotide (Linzess), making the therapy available to children as young as 2 years of age with functional constipation. Meanwhile, data presented at DDW showcased progress in IBD, including positive phase 2b results for the investigational co-antibody JNJ-4804 in refractory UC and CD, as well as encouraging phase 3 findings supporting guselkumab for perianal fistulizing CD.

Additional research presented during the month provided new insights into treatment optimization and long-term outcomes. Investigators reported improvements in esophageal distensibility among patients with EoE treated with dupilumab and shared real-world evidence suggesting favorable long-term treatment persistence with risankizumab in CD.

Here’s a look at 6 key gastroenterology headlines from May 2026 you may have missed:

FDA Approves Famotidine Injection USP Single-Dose Vials

On May 13, 2026, the FDA approved Lupin Pharmaceuticals’ Abbreviated New Drug Applications for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials, bioequivalent to the reference listed drug (RLD), Pepcid Injection, 10 mg/mL of Merck Sharp & Dohme Corp. Famotidine is a histamine-2 (H2) receptor antagonist that reduces gastric acid secretion and is used to treat gastrointestinal conditions associated with excess acid production.

FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years And Older

On May 27, 2026, the FDA approved Ironwood Pharmaceuticals’ linaclotide (Linzess) for pediatric patients ≥ 2 years of age with functional constipation (FC), expanding its previous approval for patients ≥ 6 years of age with FC.With this decision, linaclotide is now available for children ages 2-5 years with FC and remains the only FDA-approved prescription therapy for pediatric FC.

JNJ-4804 Phase 2b Data Show Higher Week-48 Remission in Refractory UC, Crohn Disease

Johnson & Johnson announced phase 2b results for the investigational co-antibody JNJ-4804 in adults with moderately to severely active UC or CD who had inadequate response or intolerance to systemic therapies, including a heavily pretreated subgroup with failure of ≥ 2 systemic therapy classes.

Data from the DUET-CD and DUET-UC studies were presented at DDW 2026 in Chicago, IL, and showed the fixed-dose combination outperformed golimumab and was numerically higher than guselkumab on several week-48 efficacy measures in the overall study populations, with larger relative differences described in the highly refractory subgroup.

DUET-UC Data Highlight Potential of Dual-Pathway Targeting in Refractory Ulcerative Colitis

Is Dual-Target Therapy the Future of Ulcerative Colitis? New Phase 2b JNJ-4804 Data

REMODEL: Dupilumab Improves Esophageal Distensibility in EoE at 24 Weeks

Results from the randomized, double-blind phase of the phase 4 REMODEL trial indicate that dupilumab significantly improved esophageal distensibility in adults with active eosinophilic esophagitis (EoE) compared with placebo at 24 weeks. The findings, which were presented at DDW 2026 in Chicago, IL, by Evan Dellon, MD, a professor of medicine and adjunct professor of epidemiology at the University of North Carolina School of Medicine in Chapel Hill, suggest that the IL-4/IL-13 pathway inhibitor not only addresses mucosal inflammation in EoE but also produces measurable improvements in a functional marker of fibrostenotic disease, a dimension of EoE pathology that has historically lacked dedicated therapeutic evidence.

Dupilumab Improves Esophageal Distensibility in EoE, With Evan Dellon, MD, MPH

Dupilumab and Esophageal Distensibility in EoE: REMODEL Trial Data

Guselkumab Shows Efficacy in Perianal Fistulizing Crohn's Disease in Phase 3 FUZION Trial

Guselkumab (Tremfya) demonstrated significantly increased rates of combined fistula remission compared with placebo at week 24 in the phase 3 FUZION trial, marking what investigators describe as the first randomized controlled trial of an approved IBD therapy to show efficacy in perianal fistulizing Crohn's disease in 2 decades. The data from Johnson & Johnson were presented as late-breaking findings at DDW 2026.

Phase 3 FUZION Data Support Guselkumab in Perianal Fistulizing Crohn’s Disease

Guselkumab for Perianal Crohn’s Disease: Phase 3 FUZION Results Explained

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

With a growing roster of advanced therapies available for CD, treatment sequencing has become one of the most consequential decisions a gastroenterologist makes. While clinical trial data inform efficacy and safety, they do not capture what happens over the years a patient spends on a given drug in the real world. A claims-based analysis presented at DDW 2026 in Chicago, IL, offers a different lens, taking a closer look at real-world switch rates. Gil Melmed, MD, a gastroenterologist at Cedars-Sinai, presented data from the US-payer claims database analysis examining real-world switching rates over 24 months among patients with CD initiating risankizumab, adalimumab, infliximab, ustekinumab, or vedolizumab.

Which Biologic Lasts Longest for Crohn's Disease? Real-World Switch Rate Data Explained

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

6 Gastroenterology Headlines You Missed in May 2026

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

At the 2026 American Thoracic Society (ATS) International Conference in Orlando, HCPLive spoke with 5 leading pulmonologists about late-breaking phase 3 clinical trial data across sleep apnea, PAH, MAC lung disease, tuberculosis, and COPD.

ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More | HCPLive Expert Interviews

2026 American Thoracic Society (ATS) International Conference

 in Orlando, Florida, from May 15 – 20, delivered a wave of late-breaking clinical data across 

, sleep medicine, and respiratory infectious disease. In this HCPLive Five, 5 leading physician experts break down the findings clinicians need to know, from the first oral pharmacotherapy for 

 approval to a 55% risk reduction in pulmonary arterial hypertension (PAH) to new frontiers in 

 complex lung disease (MACLD), tuberculosis (TB), and 

chronic obstructive pulmonary disease (COPD)

🫁 OSA — AD109 (aroxybutynin + atomoxetine): 39.3% AHI reduction vs 12.6% placebo. FDA Fast Track granted.

🫁 TB — Sutezolid + NAC: 10.6-point FEV

🫁 PAH — Ralinepag (prostacyclin receptor agonist): 55% clinical worsening risk reduction (HR 0.45; P <.0001).

🫁 MAC Lung Disease — ALIS: 88% culture conversion at 6 months.

🫁 COPD — Itepekimab (anti–IL-33 monoclonal antibody): 27.1% exacerbation reduction in former smokers (AERIFY-1).

Expert interviews from ATS 2026, Orlando. Experts: Patrick Strollo, MD; Robert Wallis, MD; Vallerie McLaughlin, MD; Charles Daley, MD; and Klaus Rabe, MD, PhD.

Whether you treat sleep apnea, PAH, nontuberculous mycobacteria, TB, or obstructive lung disease, these 5 interviews cover the phase 3 data shaping the next generation of respiratory care.

AD109 Oral Pill Shows Efficacy for OSA in Phase 3 Trials

AD109 Effective as Oral Agent for Obstructive Sleep Apnea, With Patrick John Strollo, MD

AD109, an investigational once-nightly oral pill combining aroxybutynin and atomoxetine, demonstrated statistically significant efficacy for OSA in the largest pharmacotherapy clinical development program ever conducted for the condition. Pooled phase 3 data from the SynAIRgy and LunAIRo trials, presented by Patrick Strollo, Jr. (University of Pittsburgh) at ATS 2026, showed a 39.3% reduction in apnea-hypopnea index (AHI) versus 12.6% with placebo in CPAP-intolerant adults.

Developer Apnimed has submitted a New Drug Application (NDA) to the FDA, which granted Fast Track designation, with a PDUFA date targeted for Q1 2027.

Novel 4-Month TB Regimen Improves Lung Function Recovery With Sutezolid and NAC

Novel 4-Month Pan-TB Regimens Show Promise for Lung Function Recovery, With Robert Wallis, MD

Novel 4-month pan-TB regimens containing investigational oxazolidinone sutezolid and N-acetylcysteine (NAC) demonstrated improved lung function recovery and fewer adverse events versus standard 6-month HRZE therapy in preliminary phase 2c data from the PanTB-HM trial, presented at ATS 2026. Robert Wallis, MD, chief science officer at the Aurum Institute and professor of medicine at Vanderbilt University, reported a 10.6-point FEV1 improvement at day 14 in patients with impaired baseline pulmonary function. The regimens target both pan-TB treatment without rifampin susceptibility testing and post-TB lung disease, including bronchiectasis, fibrosis, and cavities, a largely overlooked consequence of microbiologic cure affecting at least half of discharged patients.

Ralinepag Reduces Pulmonary Arterial Hypertension Worsening Risk by 55% in Phase 3

Ralinepag Achieves 55% Risk Reduction in PAH, With Vallerie McLaughlin, MD

Ralinepag, an investigational once-daily oral prostacyclin receptor agonist, reduced the risk of clinical worsening in PAH by 55% versus placebo (HR 0.45;

 <.0001) in the phase 3 ADVANCE OUTCOMES trial, presented at ATS 2026. Vallerie McLaughlin, MD, director of the pulmonary hypertension program at the University of Michigan, noted ralinepag's higher potency compared to existing agents and its potential for greater prostacyclin pathway activation. Secondary endpoints showed significant NT-proBNP reduction, improved 6-minute walk distance, and 47% greater odds of clinical improvement. United Therapeutics plans an FDA NDA submission in the second half of 2026.

ALIS Achieves 88% Culture Conversion in Newly Diagnosed MAC Lung Disease

ALIS Improves Symptoms in Newly Diagnosed MAC Lung Disease, With Charles Daley, MD

Amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy achieved 88% culture conversion at 6 months and meaningful respiratory symptom improvements in newly diagnosed MACLD, according to phase 3b ENCORE trial data presented at ATS 2026. Charles Daley, MD, of National Jewish Health, said the findings support earlier ALIS initiation rather than reserving it for refractory disease—a shift from current practice.

Itepekimab Cuts COPD Exacerbations in Former Smokers in Phase 3 AERIFY-1 Trial

Phase 3 AERIFY Shows Potential of Itepekimab in COPD, With Klaus F. Rabe, MD, PhD

Itepekimab, an anti–IL-33 monoclonal antibody, reduced annualized moderate-to-severe COPD exacerbation rates by 27.1% in former smokers in the phase 3 AERIFY-1 trial but failed to replicate statistically significant results in the nearly identical AERIFY-2 trial—a discordance Klaus Friedrich Rabe, MD, PhD, of LungenClinic Grosshansdorf, discussed at ATS 2026. Rabe attributed the divergence partly to COVID-19 pandemic-era variability affecting exacerbation rates across study sites.

The investigational biologic targets IL-33-driven airway inflammation outside the type 2 eosinophilic phenotype addressed by existing therapies. Current smokers showed minimal benefit; the phase 3 program was designed primarily around former smokers based on prior phase 2 findings.

5 interviews in 5 minutes. Check out this HCPLive Five at ATS 2026 on late breaking data in sleep apnea, lung function recovery, PAH, lung disease, and COPD.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

HCPLive Five: Pulmonology Updates at ATS 2026

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The tail end of May 2026 saw a surge in endocrinology news, between major trial results and groundbreaking decisions from the 

. Between inhaled insulin’s approval for pediatric patients with 

 and topline data from SYNCHRONIZE-1 and TRIUMPH-1, the last 30 days have seen significant shifts all across endocrinology.

 has collected 7 of the most impactful headlines in endocrinology from last month. Catch up on any major news you may have missed below:


FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes


On May 29, 2026, the FDA approved MannKind’s inhaled insulin, Afrezza, for pediatric patients aged between 4 and 17 years with T1D or T2D. The decision came in response to positive endpoint data from the INHALE-1 study – despite failing to achieve its primary noninferiority endpoint of HbA1c reduction, the trial did demonstrate the safety of Afrezza among pediatric patients. This, taken in conjunction with existing safety data from adult trials, led to the FDA’s approval of the new indication.


FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD


On May 21, 2026, the FDA accepted a supplemental New Drug Application for finerenone, which could expand its indication to adults with T1D and 

. The administration also granted Bayer’s supplemental application Priority Review, based in large part on results from the FINE-ONE phase 3 trial, in which patients treated with finerenone saw significantly reduced urine albumin-to-creatinine ratio (UACR) compared with placebo after 6 months.


FDA Clears EndoTool IV Cloud for Inpatient IV Insulin Dosing Support


On May 14, 2026, the EndoTool IV Cloud, a cloud-based version of Glooko’s intravenous insulin dosing decision-support platform, received FDA clearance via the 510(k) pathway. Designed to assess individualized insulin doses among hospitalized patients to support clinicians during inpatient care, the device is expected to launch commercially in the US before the end of 2026.


Crinecerfont Maintains Improvements in Pediatric CAH at 2 Years, With Patricia Fechner, MD


Patients with congenital adrenal hyperplasia (CAH) who received crinecerfont demonstrated substantially lower glucocorticoid doses and reduced symptoms compared to those receiving placebo, according to 2-year data from the CAHtalyst Pediatric study. In an interview with 

, Patricia Fechner, MD, attending physician at Seattle Children’s Hospital and a professor of pediatrics at the University of Washington School of Medicine, discusses the implications of this study for a condition often limited by the risks of glucocorticoid treatment.


SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo


Boehringer Ingelheim released topline results from the phase 3 SYNCHRONIZE-1 trial in May 2026 highlighting survodutide’s substantial weight loss outcomes in patients with 

 and overweight without T2D. The investigational glucagon-GLP-1 receptor dual agonist has already received Fast Track designation in May of 2021 and Breakthrough therapy designation in September of 2024. In an interview with 

, Carel le Roux, PhD, MSC, director of the Metabolic Medicine Group at the University College of Dublin School of Medicine and global coordinating investigator of the study, highlights the weight loss dependent benefits of survodutide and the possibility of weight loss independent benefits upon further research.


Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial


Retatrutide, Eli Lilly’s investigative triple GLP-1/GIP/glucagon agonist, demonstrated substantial weight reduction among patients with overweight or obesity and ≥1 weight-related comorbidity, according to topline data from the TRIUMPH-1 trial. A total of 2339 participants were randomly assigned to 1 of 4 separate doses of retatrutide, all of which demonstrated body weight reductions >15%, versus 2.2% with placebo. Full data from the study will be presented at the American Diabetes Association (ADA) Scientific Sessions 2026 in June.


Diabetes Dialogue: ADA Scientific Sessions 2026 Preview


In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the trials, presentations, and discussions they’re looking forward to at ADA 2026. Isaacs and Bellini highlight the myriad GLP-1 RA therapies expected to dominate the conference, as well as pointing out new insulin titration tools driven by continuous glucose monitor (CGM) such as Dexcom’s Smart Basal feature. The hosts express their excitement for the variety of updates to be presented at the conference in June.

Articles

Late May 2026 brought multiple regulatory and clinical inflection points in endocrinology. The FDA expanded Afrezza to children and adolescents with type 1 or type 2 diabetes, advanced finerenone toward a potential type 1 diabetes CKD indication via Priority Review, and cleared a cloud-based inpatient IV insulin decision-support tool. New data highlighted disease-modifying potential in congenital adrenal hyperplasia with crinecerfont and robust anti-obesity efficacy with next-generation incretin agonists survodutide and retatrutide. Attention now shifts to ADA 2026 updates on GLP-1–centric pipelines and CGM-enabled titration.

Catch up on major trial results, key FDA decisions, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

7 Endocrinology Headlines You Missed in May 2026

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

https://www.hcplive.com/clinical/fda-news

May 2026 brought significant developments across 

, from regulatory milestones to advances in precision medicine and disease management.

These developments were highlighted by the 

 (FDA)'s Priority Review of finerenone (Kerendia) for adults with type 1 diabetes and 

, signaling a potential expansion of treatment options for a high-risk population. Precision medicine also took center stage, with investigators demonstrating that a novel 9-protein plasma risk score could identify APOL1 high-risk individuals most likely to progress to kidney failure years before traditional markers such as eGFR decline or albuminuria emerge. Meanwhile, growing attention to APOL1-mediated kidney disease (AMKD) and

reflected an ongoing shift toward mechanism-based care, with experts emphasizing earlier diagnosis, targeted therapeutic strategies, genetic risk assessment, and evolving definitions of disease remission.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

On May 21, 2026, Bayer announced the FDA had accepted a supplemental New Drug Application (sNDA) and granted Priority Review for finerenone (Kerendia) in adults with type 1 diabetes and chronic kidney disease (CKD), based on positive results from the phase 3 FINE-ONE trial.

9-Protein Plasma Score Predicts Kidney Failure Risk in APOL1 High-Risk Individuals Before Visible CKD

A plasma proteomic risk score composed of 9 circulating proteins identified APOL1 high-risk individuals most likely to progress to kidney failure years before conventional clinical markers, including estimated glomerular filtration rate (eGFR) decline and albuminuria, became apparent.

Derived from the Penn Medicine BioBank and validated in 2 independent cohorts, the score could help address a longstanding challenge in nephrology: determining which APOL1 carriers are most likely to develop progressive kidney disease.

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

In recognition of IgAN Awareness Day on May 14, 2026, HCPLive spoke with leading nephrologists about the evolving management of IgAN, including earlier diagnosis, treatment sequencing strategies, biomarker development, and the changing definition of remission.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

As targeted therapies move closer to clinical practice, experts highlighted ongoing challenges in AMKD, including delayed diagnosis, variable disease progression, and disparities in access to genetic testing and specialized care. For AMKD Awareness Day, HCPLive spoke with 5 experts about the field's evolution from genetic discovery to emerging precision treatment approaches.

May 2026 saw nephrology advance on multiple fronts, spanning regulation, proteomics, and mechanism-driven care. The FDA granted Priority Review to expand finerenone use to adults with type 1 diabetes and CKD following phase 3 FINE-ONE data. A 9-protein plasma risk score, derived from the Penn Medicine BioBank and validated in two cohorts, stratified APOL1 high-risk individuals years before eGFR decline or albuminuria. IgA nephropathy and APOL1-mediated kidney disease discussions emphasized earlier diagnosis, biomarker-guided sequencing, genetic testing, and evolving, clinically meaningful remission endpoints.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

4 Nephrology Headlines You Missed in May 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

7 Dermatology Headlines You Missed in May 2026

Phase 2 JASMINE data show nipocalimab achieved SRI-4 response rates of 53.5% vs 46.7% with placebo at week 24, with benefits sustained through week 52.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations. 

Expert Consensus Offers Age-Specific Guidance for Genital Psoriasis Care

Alan D. Betensley, MD, is a board-certified pulmonologist and associate professor at the Feinberg School of Medicine in Northwestern Medicine.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

ECP Linked to Improved Survival in Refractory Bronchiolitis Obliterans Syndrome

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Atherosclerotic Cardiovascular Disease

10 Cardiology Headlines You Missed in May 2026

Delphine Kerob, MD, is the La Roche-Posay International Scientific Director and a dermatologist for Saint Louis hospital in Paris.

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What Are the Lasting Consequences of Childhood-Onset Atopic Dermatitis?

Marcus Shaker, MD, a professor of pediatrics and medicine at the Dartmouth Geisel School of Medicine

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

Latest News

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation

6 Gastroenterology Headlines You Missed in May 2026

HCPLive Five: Pulmonology Updates at ATS 2026

7 Endocrinology Headlines You Missed in May 2026

4 Nephrology Headlines You Missed in May 2026